217 related articles for article (PubMed ID: 7928215)
1. The question of dose for gadolinium chelates in magnetic resonance imaging.
Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
Invest Radiol; 1994 Jun; 29 Suppl 2():S154-6. PubMed ID: 7928215
[No Abstract] [Full Text] [Related]
2. Acute hemodynamic effects of nonionic and ionic magnetic resonance contrast media in intravenous bolus injection in rats.
Masui T; Takehara Y; Aoshima R; Kaneko M
Invest Radiol; 1994 Jun; 29 Suppl 2():S189-91. PubMed ID: 7928226
[No Abstract] [Full Text] [Related]
3. [Artificial contrasting during magnetic resonance tomography].
Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
[No Abstract] [Full Text] [Related]
4. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine.
Witte RJ; Anzai LL
AJNR Am J Neuroradiol; 1994 Mar; 15(3):523-4. PubMed ID: 8197951
[TBL] [Abstract][Full Text] [Related]
5. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].
Campos A; Aznar L; Alamar R; Castelló JV
Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023
[No Abstract] [Full Text] [Related]
6. High-dose contrast-enhanced MRI in multiple sclerosis.
Koudriavtseva T; Pozzilli C; Di Biasi C; Iannilli M; Trasimeni G; Gasperini C; Argentino C; Gualdi GF
Neuroradiology; 1996 May; 38 Suppl 1():S5-9. PubMed ID: 8811671
[TBL] [Abstract][Full Text] [Related]
7. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents.
Puttagunta NR; Gibby WA; Smith GT
Invest Radiol; 1996 Dec; 31(12):739-42. PubMed ID: 8970874
[TBL] [Abstract][Full Text] [Related]
8. Measurement of relative cerebral blood volume changes with visual stimulation by 'double-dose' gadopentetate-dimeglumine-enhanced dynamic magnetic resonance imaging.
Frank JA; Mattay VS; Duyn J; Sobering G; Barrios FA; Zigun J; Sexton R; Kwok P; Woo J; Moonen C
Invest Radiol; 1994 Jun; 29 Suppl 2():S157-60. PubMed ID: 7928216
[No Abstract] [Full Text] [Related]
9. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
Tweedle MF; Wedeking P; Kumar K
Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
[TBL] [Abstract][Full Text] [Related]
10. Safety and medico-legal implications of intra-articular gadolinium use.
Balkissoon AR
Semin Ultrasound CT MR; 1997 Aug; 18(4):276-7. PubMed ID: 9285995
[No Abstract] [Full Text] [Related]
11. Sonographic guidance of needle position for MR arthrography of the shoulder.
Valls R; Melloni P
AJR Am J Roentgenol; 1997 Sep; 169(3):845-7. PubMed ID: 9275909
[No Abstract] [Full Text] [Related]
12. Brain distribution of MRI contrast media in rats after intracisternal injection.
Allard M; Kien P; Caille JM; Bonnemain B; Simonnet G
J Neuroradiol; 1987; 14(4):383-7. PubMed ID: 3131496
[No Abstract] [Full Text] [Related]
13. Total cerebrospinal fluid enhancement following intravenous Gd-DTPA administration in a case of meningiomatosis.
Berger B; Ortiz O; Gold A; Hilal SK
AJNR Am J Neuroradiol; 1992; 13(1):15-8. PubMed ID: 1595433
[No Abstract] [Full Text] [Related]
14. [The magnetic resonance tomography of osteochondrosis dissecans of the knee joint after intravenous gadolinium-DTPA administration].
Adam G; Neuerburg J; Peiss J; Bohndorf K; Günther RW
Rofo; 1994 May; 160(5):459-64. PubMed ID: 8173056
[TBL] [Abstract][Full Text] [Related]
15. Detection of hepatocellular carcinoma with dynamic MR imaging during intraarterial infusion of gadopentetate dimeglumine.
Fujita T; Ito K; Choji T; Honjo K; Matsumoto T; Arita T; Nakanishi T
AJR Am J Roentgenol; 1994 Oct; 163(4):865-6. PubMed ID: 8092025
[No Abstract] [Full Text] [Related]
16. Dose of contrast material in the MR imaging evaluation of central nervous system tumors.
Yuh WT; Halloran JI; Mayr NA; Fisher DJ; Nguyen HD; Simonson TM
J Magn Reson Imaging; 1994; 4(3):243-9. PubMed ID: 8061421
[No Abstract] [Full Text] [Related]
17. [Double-dose Gd-DTPA: detectability of intraparenchymal brain metastasis].
Tatsuno S; Hata Y; Tada S
Nihon Igaku Hoshasen Gakkai Zasshi; 1996 Oct; 56(12):855-9. PubMed ID: 8940816
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of contrast media in magnetic resonance imaging.
Bydder GM
Br J Hosp Med; 1990 Feb; 43(2):149-52. PubMed ID: 2178714
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial.
Niendorf HP; Haustein J; Louton T; Beck W; Laniado M
Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134
[No Abstract] [Full Text] [Related]
20. Dosage of gadoteridol and adverse reactions relative to gadopentetate.
Hieronim DE; Kanal E; Swanson DP
Am J Health Syst Pharm; 1995 Nov; 52(22):2556-9. PubMed ID: 8590239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
